The Latest Breaking News from Tricida

Within the last quarter, Tricida (NASDAQ:TCDA) has observed the following analyst ratings:

Tricida Inc (NASDAQ:TCDA) said that, as anticipated, it is stopping its VALOR-CKD renal outcomes trial early for administrative reasons under the existing study protocol to allow for six months of financial runway following topline results, currently anticipated in early Q4 2022.   VALOR-CKD trial, initiated in 2018, was designed to evaluate veverimer's ability to…

Tricida (NASDAQ:TCDA) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Tricida beat estimated earnings by 42.86%, reporting an EPS of $-0.4 versus an estimate of $-0.7.

Tricida (NASDAQ:TCDA) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Tricida will report an earnings per share (EPS) of $-0.70.